UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Clinical trials for UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made vaccine takes on tough breast cancer
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized vaccine made from a patient's own tumor, given alone or with drugs that boost the immune system (pembrolizumab or ipilimumab). The goal is to see if the vaccine is safe and can help the immune system fight triple negative breast cancer …
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: Emory University • Aim: ⭐️ VACCINE ⭐️
Last updated May 11, 2026 20:37 UTC
-
New triple-drug combo targets hard-to-treat breast cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing whether adding an experimental drug (ZEN003694) to standard immunotherapy (pembrolizumab) and chemotherapy (nab-paclitaxel) is safe and tolerable for people with advanced triple-negative breast cancer that has spread. About 57 participants will r…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Tailor-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
New drug duo targets hard-to-treat HER2 cancers in early trial
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of two drugs given together for people with advanced breast cancer or other solid tumors that have a protein called HER2. The drugs are pidnarulex (which stops cancer cells from repairing themselves) and trastuzumab deruxtecan…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New hope for tough breast cancer: early trial combines three drugs
Disease control Recruiting nowThis early-phase study tests a new drug, ASTX727, added to standard chemotherapy and immunotherapy for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination can shrink or stabilize tu…
Matched conditions: UNRESECTABLE TRIPLE-NEGATIVE BREAST CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 08, 2026 12:01 UTC